News
The FDA has approved the Genio® system for treating patients with moderate to severe obstructive sleep apnea (OSA) with an ...
InvestorsHub on MSN3d
Nyxoah Shares Climb Following FDA Clearance of Genio Device for Sleep Apnea Treatment
Nyxoah SA (NASDAQ:NYXH) saw its stock rise 9.4% after the FDA granted approval for its Genio system designed to treat ...
The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.
Medical Device Network on MSN3d
FDA approves Nyxoah’s Genio system for obstructive sleep apnoea
The system is compatible with 1.5T and 3T magnetic resonance imaging scans and eliminates the need for an implanted battery.
Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to its recently-cleared offering, Genio.
Genio is a different approach to hypoglossal nerve stimulation (HGNS) for the treatment of OSA. Genio’s unique design ...
Investing.com -- Nyxoah SA (BR:NYXH) (NASDAQ: NYXH) stock jumped 9.4% following FDA approval of its Genio system for treating moderate to severe obstructive sleep apnea (OSA).
Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, ...
Nyxoah announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback